Results 71 to 80 of about 1,056 (174)

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

Aging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu, Ming Yang, Fugang Xiao, Jinrong Zeng   +3 more
wiley   +1 more source

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

, 2023
Prurigo nodularis (PN) or chronic nodular prurigo is a debilitating, and severely pruritic neuroimmune skin disease, predominantly characterized by the presence of multiple pruriginous nodules symmetrically distributed in large areas of the trunk and ...
Franz J Legat, Luigi  Naldi, Alan Fleischer, Fleischer, Alan, Shawn G Kwatra, Legat, Franz J, Silverberg, Jonathan I, Jabbar-Lopez, Zarif, Gharib, Rola, Jonathan I Silverberg, Reich, Adam, Piketty, Christophe, Dagmar Simon, Ständer, Sonja, Paul, Carle, Simon, Dagmar, Adam Reich, Faiz Ahmad, Zarif Jabbar-Lopez, Vivian T Laquer, Christophe Piketty, Gil Yosipovitch, Laquer, Vivian T, Naldi, Luigi , Kwatra, Shawn G, Carle Paul, Sonja Ständer, Rola Gharib, Ahmad, Faiz, Yosipovitch, Gil   +29 more
core   +1 more source

Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports

Acta Dermato-Venereologica
is missing (Short communication)
Michie Katsuta, Ryoichi Kamide, Yozo Ishiuji, Yoshimasa Nobeyama, Akihiko Asahina   +4 more
doaj   +1 more source

Table_1_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.docx

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

Background: Atopic dermatitis (AD) is a common, chronic, relapsing, pruritic, neuroimmune skin disease, requiring long-term symptom control. Objectives: The ARCADIA long-term extension (LTE) study evaluates nemolizumab safety and efficacy in ≥12-year-old
Alpizar, Sady, Gold, Linda Stein, Galus, Ryszard, Maintz, Laura, Sidbury, Robert, Papp, Kim A., Augustin, Matthias, Barber, Kirk, Kaszuba, Andrzej, Laquer, Vivian, Zirwas, Matthew, Reich, Adam, De Bruin-Weller, Marjolein S., Trullenque, Gretel, Drahos, Agnes, Cheong, Soo Yeon, Thaçi, Diamant, Ulianov, Liliana, Silverberg, Jonathan I., Peris, Ketty, Infection & Immunity, Son, Sang Wook, Tauber, Marie, Nahm, Walter K., MS Dermatologie/Allergologie, Piketty, Christophe, Ryzhkova, Anna   +26 more
core   +3 more sources

Recent advances in treatment of prurigo nodularis

Dermatologica Sinica
Prurigo nodularis is a chronic skin condition which has significant negative impacts on the psychosocial function and quality of life of affected patients.
Chieh-Hsun Chen, Stephen Chu-Sung Hu
doaj   +1 more source

Table_3_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.docx

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source

From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis

Allergy, Volume 81, Issue 7, Page 2565-2567, July 2026.
Thomas Bieber, Felix Lauffer
wiley   +1 more source

P052 Nemolizumab elicits rapid itch-free state and sleep improvement in prurigo nodularis

There is a need for rapid management of the debilitating symptoms of prurigo nodularis (PN), particularly the characteristically severe pruritus. Nemolizumab blocks interleukin (IL)-31, the first neuroimmune cytokine described to directly trigger ...
Elmariah, Sarina, Kim, Brian, Pink, Andrew E, Sauder, Maxwell, Legat, Franz J, Silverberg, Jonathan I, Jabbar-Lopez, Zarif, Kwatra, Shawn G, da Silva Santos, Carla S, Piketty, Christophe, Chen, Xiaoxiao, Ständer, Sonja, Metz, Martin, Yosipovitch, Gil, Noda, Aliene   +14 more
core   +1 more source

Image_3_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.tif

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source